Core Viewpoint - The company, 荃信生物-B (02509), has seen its stock price increase by 3.26%, reaching HKD 20.9, with a trading volume of HKD 3.0619 million, following the announcement of a milestone payment from its partner Caldera Therapeutics, Inc. [1] Group 1 - The company received a milestone payment of USD 5 million from Caldera Therapeutics, Inc. triggered by the approval of QX030N/CLD-423 for human research ethics committee Phase I clinical trial [1] - The dual antibody QX030N/CLD-423 has been approved by the Human Research Ethics Committee (HREC) in Australia and is planned to initiate clinical trials in early 2026 [1] - This approval marks the company's entry into the clinical stage for its dual antibody matrix layout overseas, further strengthening its leading position in the fields of autoimmune and allergic diseases [1]
港股异动 | 荃信生物-B(02509)再涨超3% 双抗矩阵布局在海外正式迈入临床阶段